Optimi Health Corp. is a commercial-stage pharmaceutical company. The Company focuses on manufacturing and distributing good manufacturing practices (GMP) grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the Company produces validated Methylenedioxymethamphetamine hydrochloride (MDMA) and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. It supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program. With its vertically integrated approach, the Company owns and operates two purpose-built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada.